Objective
The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.
There is heterogeneity in who develops diabetes, the rate at which their subsequent diabetes progresses, how they respond to diabetes therapy and who develops micro- and macrovascular complications. In the DIRECT consortium we propose to identify biomarkers to identify subtypes with rapid diabetes development and progression and altered response to diabetes treatments, and develop and use these biomarkers in clinical trials.
Two phenotyping work packages will focus on glycaemic deterioration and therapeutic response. For each, the DIRECT consortium brings considerable existing resource, which will be augmented by large-scale prospective cohort collection with intensive physiological and imaging phenotyping. Additional data will be added, such as existing studies on acute response to intravenous beta-cell secretagogues, and functional genomics on human islets, liver, muscle and adipose tissue, to maximise the power and utility of an innovative integrated biology approach. To enable computational multi-level integration across phenotypes and data types, a robust and secure data repository will be developed with strict data governance. As the ultimate aim of DIRECT is patient stratification, biomarkers arising from the discovery work will be used to design one or more prospective clinical trials. These will validate the biomarker(s) of interest, and establish utility in clinical practice and/or trial design and drug development. As a result, this consortium offers considerable potential to achieve major progress towards a personalized medicines approach to the treatment of type 2 diabetes.
Fields of science
Call for proposal
IMI-JU-03-2010
See other projects for this call
Coordinator
65929 Frankfurt Am Main
Germany
See on map
Participants (25)
DD1 4HN Dundee
See on map
BA2 7AY Bath
See on map
00185 Roma
See on map
2800 Kongens Lyngby
See on map
72074 Tuebingen
See on map
85764 Neuherberg
See on map
08036 Barcelona
See on map
SW7 2AZ LONDON
See on map
100 44 Stockholm
See on map
75794 Paris
See on map
2333 ZA Leiden
See on map
1165 Kobenhavn
See on map
70211 KUOPIO
See on map
22100 Lund
See on map
NE1 7RU Newcastle Upon Tyne
See on map
EX4 4QJ Exeter
See on map
1211 Geneve
See on map
OX1 2JD Oxford
See on map
89081 Ulm
See on map
1081 HV Amsterdam
See on map
2880 Bagsvaerd
See on map
RG21 4FA Basingstoke
See on map
91190 GIF-SUR-YVETTE
See on map
59037 Lille
See on map
55218 Ingelheim
See on map